To the Editor: We read the study by Lauck et al1 with
great interest. This large retrospective cohort study
focused on the risk of skin cancer following biologic
therapy in patients with inflammatory diseases. By
using propensity score matching to control for
confounding factors related to the underlying diseases, the study provides valuable insight into the
individualized selection of biologic therapies in
clinical practice. However, we believe there are 2
key aspects that warrant further discussion.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类|1 区医学
小类|1 区皮肤病学
最新[2025]版：
大类|1 区医学
小类|1 区皮肤病学
第一作者：
第一作者机构：[1]Department of Anorectal Surgery, Ningbo No.2 Hospital, Ningbo, Zhejiang.
通讯作者：
推荐引用方式(GB/T 7714)：
Li Sheng,Chen Cheng.Response to Lauck et al "Cutaneous malignancy after biologic therapy for inflammatory disease: An active comparator, retrospective cohort study"[J].Journal Of The American Academy Of Dermatology.2025,doi:10.1016/j.jaad.2025.08.118.
APA：
Li Sheng&Chen Cheng.(2025).Response to Lauck et al "Cutaneous malignancy after biologic therapy for inflammatory disease: An active comparator, retrospective cohort study".Journal Of The American Academy Of Dermatology,,
MLA：
Li Sheng,et al."Response to Lauck et al "Cutaneous malignancy after biologic therapy for inflammatory disease: An active comparator, retrospective cohort study"".Journal Of The American Academy Of Dermatology .(2025)
医学